Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats

Sang Youb Han, Cy Hyun Kim, Han Seong Kim, Yi Hwa Jee, Hye Kyoung Song, Mi Hwa Lee, Kum Hyun Han, Hyoung Kyu Kim, Young Sun Kang, Jee Young Han, Young Sik Kim, Dae-Ryong Cha

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

Aldosterone induces myocardial fibrosis and vascular inflammation via proinflammatory and profibrotic cytokines. The effect of spironolactone on renal inflammation and renal function was investigated in type 2 diabetic rats. For define the molecular mechanism of spironolactone, the effect of spironolactone on the synthesis of monocyte chemotactic peptide-1 (MCP-1) and its upstream transcription factor, NF-κB, was evaluated in cultured mesangial cells and proximal tubular cells. There were no changes in blood glucose concentration or BP after spironolactone treatment. Spironolactone treatment significantly reduced urinary albumin excretion and ameliorated glomerulosclerosis. Urinary levels of MCP-1 were significantly increased concurrently with renal expression of MCP-1, macrophage migration inhibitory factor, and macrophage infiltration. Spironolactone treatment significantly inhibited urinary excretion of MCP-1 as well as renal MCP-1 and migration inhibitory factor expression and macrophage infiltration. In addition, aldosterone induced upregulation of MCP-1 expression and NF-κB transcriptional activity in cultured cells, and spironolactone reduced both NF-κB activation and MCP-1 synthesis. Furthermore, NF-κB inhibition abolished aldosterone-induced MCP-1 production. Overall, these findings suggest that aldosterone-induced NF-κB activation leads to activation of proinflammatory cytokines, ultimately leading to renal injury in this model. These data suggest that mineralocorticoid blockade may be a potential therapeutic target in diabetic nephropathy.

Original languageEnglish
Pages (from-to)1362-1372
Number of pages11
JournalJournal of the American Society of Nephrology
Volume17
Issue number5
DOIs
Publication statusPublished - 2006 May 1

Fingerprint

Spironolactone
Diabetic Nephropathies
Monocytes
Anti-Inflammatory Agents
Peptides
Aldosterone
Kidney
Macrophage Migration-Inhibitory Factors
Cultured Cells
Cytokines
Inflammation
Mineralocorticoids
Mesangial Cells
Blood Vessels
Blood Glucose
Albumins
Fibrosis
Transcription Factors
Up-Regulation
Macrophages

ASJC Scopus subject areas

  • Nephrology

Cite this

Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. / Han, Sang Youb; Kim, Cy Hyun; Kim, Han Seong; Jee, Yi Hwa; Song, Hye Kyoung; Lee, Mi Hwa; Han, Kum Hyun; Kim, Hyoung Kyu; Kang, Young Sun; Han, Jee Young; Kim, Young Sik; Cha, Dae-Ryong.

In: Journal of the American Society of Nephrology, Vol. 17, No. 5, 01.05.2006, p. 1362-1372.

Research output: Contribution to journalArticle

Han, Sang Youb ; Kim, Cy Hyun ; Kim, Han Seong ; Jee, Yi Hwa ; Song, Hye Kyoung ; Lee, Mi Hwa ; Han, Kum Hyun ; Kim, Hyoung Kyu ; Kang, Young Sun ; Han, Jee Young ; Kim, Young Sik ; Cha, Dae-Ryong. / Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. In: Journal of the American Society of Nephrology. 2006 ; Vol. 17, No. 5. pp. 1362-1372.
@article{7ccbf349804e4f239b1b37fdbcafa5dc,
title = "Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats",
abstract = "Aldosterone induces myocardial fibrosis and vascular inflammation via proinflammatory and profibrotic cytokines. The effect of spironolactone on renal inflammation and renal function was investigated in type 2 diabetic rats. For define the molecular mechanism of spironolactone, the effect of spironolactone on the synthesis of monocyte chemotactic peptide-1 (MCP-1) and its upstream transcription factor, NF-κB, was evaluated in cultured mesangial cells and proximal tubular cells. There were no changes in blood glucose concentration or BP after spironolactone treatment. Spironolactone treatment significantly reduced urinary albumin excretion and ameliorated glomerulosclerosis. Urinary levels of MCP-1 were significantly increased concurrently with renal expression of MCP-1, macrophage migration inhibitory factor, and macrophage infiltration. Spironolactone treatment significantly inhibited urinary excretion of MCP-1 as well as renal MCP-1 and migration inhibitory factor expression and macrophage infiltration. In addition, aldosterone induced upregulation of MCP-1 expression and NF-κB transcriptional activity in cultured cells, and spironolactone reduced both NF-κB activation and MCP-1 synthesis. Furthermore, NF-κB inhibition abolished aldosterone-induced MCP-1 production. Overall, these findings suggest that aldosterone-induced NF-κB activation leads to activation of proinflammatory cytokines, ultimately leading to renal injury in this model. These data suggest that mineralocorticoid blockade may be a potential therapeutic target in diabetic nephropathy.",
author = "Han, {Sang Youb} and Kim, {Cy Hyun} and Kim, {Han Seong} and Jee, {Yi Hwa} and Song, {Hye Kyoung} and Lee, {Mi Hwa} and Han, {Kum Hyun} and Kim, {Hyoung Kyu} and Kang, {Young Sun} and Han, {Jee Young} and Kim, {Young Sik} and Dae-Ryong Cha",
year = "2006",
month = "5",
day = "1",
doi = "10.1681/ASN.2005111196",
language = "English",
volume = "17",
pages = "1362--1372",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats

AU - Han, Sang Youb

AU - Kim, Cy Hyun

AU - Kim, Han Seong

AU - Jee, Yi Hwa

AU - Song, Hye Kyoung

AU - Lee, Mi Hwa

AU - Han, Kum Hyun

AU - Kim, Hyoung Kyu

AU - Kang, Young Sun

AU - Han, Jee Young

AU - Kim, Young Sik

AU - Cha, Dae-Ryong

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Aldosterone induces myocardial fibrosis and vascular inflammation via proinflammatory and profibrotic cytokines. The effect of spironolactone on renal inflammation and renal function was investigated in type 2 diabetic rats. For define the molecular mechanism of spironolactone, the effect of spironolactone on the synthesis of monocyte chemotactic peptide-1 (MCP-1) and its upstream transcription factor, NF-κB, was evaluated in cultured mesangial cells and proximal tubular cells. There were no changes in blood glucose concentration or BP after spironolactone treatment. Spironolactone treatment significantly reduced urinary albumin excretion and ameliorated glomerulosclerosis. Urinary levels of MCP-1 were significantly increased concurrently with renal expression of MCP-1, macrophage migration inhibitory factor, and macrophage infiltration. Spironolactone treatment significantly inhibited urinary excretion of MCP-1 as well as renal MCP-1 and migration inhibitory factor expression and macrophage infiltration. In addition, aldosterone induced upregulation of MCP-1 expression and NF-κB transcriptional activity in cultured cells, and spironolactone reduced both NF-κB activation and MCP-1 synthesis. Furthermore, NF-κB inhibition abolished aldosterone-induced MCP-1 production. Overall, these findings suggest that aldosterone-induced NF-κB activation leads to activation of proinflammatory cytokines, ultimately leading to renal injury in this model. These data suggest that mineralocorticoid blockade may be a potential therapeutic target in diabetic nephropathy.

AB - Aldosterone induces myocardial fibrosis and vascular inflammation via proinflammatory and profibrotic cytokines. The effect of spironolactone on renal inflammation and renal function was investigated in type 2 diabetic rats. For define the molecular mechanism of spironolactone, the effect of spironolactone on the synthesis of monocyte chemotactic peptide-1 (MCP-1) and its upstream transcription factor, NF-κB, was evaluated in cultured mesangial cells and proximal tubular cells. There were no changes in blood glucose concentration or BP after spironolactone treatment. Spironolactone treatment significantly reduced urinary albumin excretion and ameliorated glomerulosclerosis. Urinary levels of MCP-1 were significantly increased concurrently with renal expression of MCP-1, macrophage migration inhibitory factor, and macrophage infiltration. Spironolactone treatment significantly inhibited urinary excretion of MCP-1 as well as renal MCP-1 and migration inhibitory factor expression and macrophage infiltration. In addition, aldosterone induced upregulation of MCP-1 expression and NF-κB transcriptional activity in cultured cells, and spironolactone reduced both NF-κB activation and MCP-1 synthesis. Furthermore, NF-κB inhibition abolished aldosterone-induced MCP-1 production. Overall, these findings suggest that aldosterone-induced NF-κB activation leads to activation of proinflammatory cytokines, ultimately leading to renal injury in this model. These data suggest that mineralocorticoid blockade may be a potential therapeutic target in diabetic nephropathy.

UR - http://www.scopus.com/inward/record.url?scp=33646366660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646366660&partnerID=8YFLogxK

U2 - 10.1681/ASN.2005111196

DO - 10.1681/ASN.2005111196

M3 - Article

VL - 17

SP - 1362

EP - 1372

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 5

ER -